Sampson, J. H., Archer, G. E., Bigner, D. D., Davis, T., Friedman, H. S., Keler, T., … Heimberger, A. B. (2008). Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. Journal of Clinical Oncology, 26(15_suppl), 2011–2011. https://doi.org/10.1200/jco.2008.26.15_suppl.2011

Sampson, J. H., G. E. Archer, D. D. Bigner, T. Davis, H. S. Friedman, T. Keler, D. A. Mitchell, D. A. Reardon, R. Sawaya, and A. B. Heimberger. “Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 2011–2011. https://doi.org/10.1200/jco.2008.26.15_suppl.2011.

Sampson JH, Archer GE, Bigner DD, Davis T, Friedman HS, Keler T, et al. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. Journal of Clinical Oncology. 2008 May 20;26(15_suppl):2011–2011.

Sampson, J. H., et al. “Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM.” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2008, pp. 2011–2011. Crossref, doi:10.1200/jco.2008.26.15_suppl.2011.

Sampson JH, Archer GE, Bigner DD, Davis T, Friedman HS, Keler T, Mitchell DA, Reardon DA, Sawaya R, Heimberger AB. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008 May 20;26(15_suppl):2011–2011.